MGMT and glioblastoma: Upon IL13Rα2-targeted CAR-T cells administered to IDH-wild type, unmethylated MGMT gene expressed recurrent GBM patients, all intracranial and spinal tumours regressed with enhanced levels of immune cells detected in the cerebrospinal fluid, demonstrating immune system activation for up to 7.5 months.